Celldex Therapeutics’ (CLDX) Buy Rating Reaffirmed at HC Wainwright

Posted by Brenda Bartman on Oct 2nd, 2026

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They currently have a $64.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 98.73% from the company’s previous close.

A number of other analysts have also weighed in on CLDX. Stifel Nicolaus set a $68.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday, September 22nd. Guggenheim raised their price target on shares of Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, July 20th. UBS Group raised their price target on shares of Celldex Therapeutics from $38.00 to $45.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Leerink Partners lifted their price target on shares of Celldex Therapeutics from $70.00 to $88.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 23rd. Finally, Cantor Fitzgerald lifted their price target on shares of Celldex Therapeutics from $61.00 to $72.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 22nd. One research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $61.92.

Get Our Latest Stock Analysis on Celldex Therapeutics

Celldex Therapeutics Stock Up 0.1%

Shares of NASDAQ:CLDX traded up $0.03 on Friday, hitting $32.21. The company had a trading volume of 334,310 shares, compared to its average volume of 1,053,606. The firm’s 50-day simple moving average is $38.45 and its two-hundred day simple moving average is $34.91. Celldex Therapeutics has a 1 year low of $22.10 and a 1 year high of $45.14. The firm has a market capitalization of $2.53 billion, a price-to-earnings ratio of -7.41 and a beta of 0.90.

Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.12. The company had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.74 million. Equities research analysts anticipate that Celldex Therapeutics will post -4.17 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP lifted its position in shares of Celldex Therapeutics by 11.5% during the second quarter. Wellington Management Group LLP now owns 9,543,671 shares of the biopharmaceutical company’s stock valued at $355,120,000 after buying an additional 983,195 shares during the last quarter. Elmind Capital LP purchased a new position in shares of Celldex Therapeutics in the 4th quarter valued at approximately $23,493,000. Assenagon Asset Management S.A. raised its position in shares of Celldex Therapeutics by 438.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 788,696 shares of the biopharmaceutical company’s stock valued at $29,347,000 after purchasing an additional 642,171 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Celldex Therapeutics by 62.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,059,534 shares of the biopharmaceutical company’s stock valued at $33,596,000 after purchasing an additional 407,818 shares during the last quarter. Finally, Eversept Partners LP increased its holdings in Celldex Therapeutics by 24.6% in the 1st quarter. Eversept Partners LP now owns 1,788,016 shares of the biopharmaceutical company’s stock worth $56,716,000 after buying an additional 353,291 shares during the period.

Celldex Therapeutics Company Profile

(Get Free Report)

Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for diseases with significant unmet medical needs. The company’s research programs target mast cell–mediated disorders, inflammatory diseases, and cancer, using engineered antibodies designed to modulate specific immune-system pathways.

Celldex’s lead product candidate is barzolvolimab, an investigational monoclonal antibody that targets the KIT receptor on mast cells.